טוען...

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma

Previous results suggest that GEM affects 5-fluorouracil (5-FU) metabolism and pharmacokinetics in cancer patients, while combined with oxaliplatin, levo-folinic acid, and 5-FU (GOLF regimen), at doses achievable in cancer patients, determines high cytotoxic and proapoptotic antitumour activity in c...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
Main Authors:	Correale, P, Messinese, S, Caraglia, M, Marsili, S, Piccolomini, A, Petrioli, R, Ceciarini, F, Micheli, L, Nencini, C, Neri, A, Vuolo, G, Guarnieri, A, Abbruzzese, A, Prete, S D, Giorgi, G, Francini, G
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Publishing Group 2004
נושאים:	Clinical
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2409742/ https://ncbi.nlm.nih.gov/pubmed/15150625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601783
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma

פריטים דומים